EN Mobile Logo



ADA's Scientific Sessions 2016

The American Diabetes Association's 76th Scientific Sessions were held in New Orleans, LA from June 10-14, 2016.





Recent Content

Investigators examined cardiovascular risk with the new basal insulin peglispro compared to insulin glargine or NPH in diabetic patients.

A 20-year study examined the long-term effect of cardiorespiratory fitness on risk of developing prediabetes or diabetes.

Aging may be beneficial to diabetes patients. Recent findings suggest a cellular aging process may, unexpectedly, enhance insulin secretion.

A secondary analysis of data from the Insulin Resistance Intervention after Stroke trial (IRIS) examined pioglitazone’s effect on diabetes prevention.

The first at-home study to test the efficacy & safety of a fully automated, dual hormone (glucagon and insulin) bionic pancreas was presented at ADA.

A study tested the impact of intensive lifestyle intervention in low-income African Americans with type 2 diabetes. Results were shared at ADA.

Investigators compared initial therapy with canagliflozin plus metformin to metformin monotherapy in drug naïve type 2 diabetes patients.

By clicking Accept, you agree to become a member of the UBM Medica Community.